MRI contrast media calculator — gadolinium (GBCA)

AI-enhanced · live

Examination & patient

Select exam · demographics · renal function · adult & pediatric

Examination (by organ)

Select an examination…

Age (yr)

Sex

Weight (kg)

Height (cm)

Creatinine (µmol/L)

GBCA agent

Concentration (mmol/mL)

Standard dose (mmol/kg)

Agent safety group (ACR)

Prior Gd exposures (12 mo)

–

BMI

–

BSA m²

–

LBW kg (adult)

–

eGFR (CKD-EPI)

Protocol reference library

Study	Adult	Child	Rate
MRI brain / spine	0.1 mmol/kg	0.1 mmol/kg	1.5–2
Breast / liver / prostate	0.1 mmol/kg	0.1 mmol/kg	2–2.5
Hepatobiliary (EOB)	0.025 mmol/kg	0.0125 mmol/kg	1–2
CMR — LGE	0.1–0.2 mmol/kg	0.1–0.2 mmol/kg	2–3
CMR — perfusion	0.05–0.1 mmol/kg	0.05–0.1 mmol/kg	4–5
CE-MRA	0.1 mmol/kg	0.1 mmol/kg	1–2
Ambelvist (any region)	0.01 mmol/kg	0.01 mmol/kg	1–4

Pediatric eGFR uses the bedside Schwartz equation (0.413 × height / SCr). GBCA dosing in children is weight-based at the same mmol/kg — fixed dosing is inappropriate. Gadobutrol, gadoterate, gadoteridol and gadoquatrane (Ambelvist) are approved from term neonates; gadopiclenol is adults-only. Check local labeling.

Injection protocol

Delivery · NSF risk · cumulative exposure · cost

Injection rate (mL/s)

Contrast volume (mL)

Saline flush (mL)

GBCA cost ($/mL)

Gadolinium load–

Dose administered–

Injection duration–

Gd delivery rate–

NSF risk category–

Cumulative exposure (12 mo)–

Cost analysis

Contrast cost / study–

Saline cost / study–

Total / study–

Cost per mmol Gd–

Annual projection & savings

Studies / year

Annual total cost–

Fixed → weight-dosed savings / yr–

Dose recommendations

Fixed · weight · pediatric · LBW + eGFR · BSA — with NSF guidance

Method	Factor	mL	mmol Gd
Fixed dose	mL	–	–
Weight-based	mmol/kg	–	–
Pediatric weight-based	mmol/kg	–	–
★ LBW + eGFR adj.	mmol/kg	–	–
BSA-based	mmol/m²	–	–

★ AI-recommended — adults: LBW + eGFR (eGFR <30: half dose with group II; group I contraindicated). Children: weight-based at the labeled dose (Ambelvist 0.01 mmol/kg = 0.04 mmol Gd/kg). LBW/BSA formulas are adult-derived. Factors editable per site protocol.

AI insight…

eGFR thresholds — NSF risk stratification (ACR / ESUR guidance)

eGFR ≥60 — low risk

Any approved agent acceptable at standard dose. Proceed routinely. In children, use the single lowest adequate dose.

eGFR 30–59 — caution

Prefer group II agents; avoid group I linear agents when possible, especially eGFR <45. Single lowest adequate dose.

eGFR 15–29 — high risk

Group I contraindicated. Group II at ≤0.1 mmol/kg, single administration; avoid repeat within 7 days. Document shared decision.

eGFR <15 / dialysis — very high

Avoid unless essential — group II only, nephrology input, informed consent; consider non-contrast alternatives (TOF, ASL, DWI).

Reference: ACR Manual on Contrast Media (current edition) · ESUR Guidelines v10 · FDA/EMA GBCA safety communications. Ambelvist (gadoquatrane) — FDA initial approval June 2026 (Japan March 2026); not yet authorized in EU/other markets at time of writing. Verify against latest published versions and institutional protocol.

Injection profile monitor

select exam

Injection phase Distribution / washout Simplified two-compartment model — educational use

Estimates only — not a medical device. Clinical decisions remain with the treating team. © SATMED Health · MRI module